a5 Earnings inflection · 89 dossiers

Beaten-down SMR re-activated on a NEW binary: South Korea''s $200B US-investment package is eyeing NuScale''s Tennessee/TVA program (Doosan + Samsung C&T in talks). But the tape is pure rip-fade (+9% 6/2 → −13% 6/3 to $12.13), fundamentals…

Busted-platform turnaround: ABCL re-rated ~74% in 90d off the $2.09 low on ABCL635 Phase 1 success + Q1 revenue beat (+98% YoY) + clustered upgrades. The Q3 2026 ABCL635 Phase 2 VMS topline is the binary that re-rates it — but it''s months…

Cannabis-reschedule sentiment beta — but ACB is the WRONG horse: a Canadian LP with zero U.S. THC ops, so the April 24 Schedule-III/280E catalyst doesn''t accrue. Sitting near 52wk low ($3.46 vs $6.67 high); June 11 earnings + June 29 DEA…

BNPL narrative MATURING into consumer-credit stress cycle; Citizens cut PT to $85 on 2026-04-17 signaling sell-side decelerating. Next binary is Q3 FY26 print ~2026-05-08 — GMV growth and 30+ delinquency rate decide whether this is a fresh…

Sub-$2 ethanol / specialty-alcohol washout with DEAD narrative — no flow, no re-rating, no retail velocity. Strictly archetype-5 binary on the ~2026-05-07 Q1 print or an intra-quarter 8-K step-function (Pekin sale, JV, refi). 3-day…

2x-leveraged AMD wrapper sitting on an 11-day parabolic run (longest since 2005) into a binary Q1 print on 2026-04-30. Narrative real (MI400/OpenAI/Meta) but every beginner-trap flag is on: RSI>75, 18% stretched above 20-EMA underlying,…

AMZU = Direxion Daily AMZN Bull 2X leveraged ETF. Thesis is just "2x-expression of AMZN's AI/AWS narrative into the Q1 2026 print (~late-April/early-May)". Theme-tag "M&A/activism/special-sits" is a discovery-engine mis-label — flag and…

No trade — complete data vacuum. AMZZ tagged into m-and-a-activism-special-sits bucket on 2026-04-20 but zero headlines, zero filings, zero price context. Dormant until a 13D, definitive merger agreement, or tender offer surfaces.…

Pure-play next-gen Dupixent disruptor with half-life-extended IL-13/IL-4Rα/OX40L antibodies; APG777 Part B dose-optimization data in atopic dermatitis is the next binary. DORMANT — framework-ready, not actively in play without fresh price…

Biogen-deal re-rating (2026-04-06) already digested; Wells Fargo Equal-Weight at $41 PT (2026-04-17) caps upside. Next impulse is binary on ~2026-05-06 Q1 print — Syfovre net revs + Empaveli C3G ramp. MATURING, not ACCELERATING. Watch-only.

Consolidated-psychedelic-leader narrative (AtaiBeckley merger + 22.4% Compass stake, both COMP360 Phase 3 trials positive, BPL-003 EOP2 cleared) has ALREADY fired. Tape rolled from [entry redacted] to $4.53 with no hard data catalyst until…

AVNS agreed 2026-04-14 to go private at $1.272B all-cash to American Industrial Partners — narrative is DEAD and replaced by merger-arb pin. No momentum trade here; tape will flatline into close. Skip for our playbook.

Deep-cyclical Brazilian petrochem, NOT a momentum name. Only live angle is the perennial Novonor stake-sale + Braskem Idesa debt-restructuring binary. Nothing accelerating now; the Q1 print (2026-05-13) bounce already faded. Skip until a…

[Stage 1 WATCH] small-cap-ai tag but it''s CPaaS post-Q1 (archetype-5), single B.Riley PT, no chorus, no accelerating narrative leg — RSI 82.5 parabolic momentum reading without a fresh driver.

Broken-IPO falling knife: BTGO down ~69% from its $18 IPO (Jan 2026) to $5.61, sitting on all-time lows after a Q1 EBITDA miss, with a July lockup overhang. Real crypto-custody franchise but dead tape — avoid until a base forms; only live…

Iran-war/Hormuz freight-spike that drove BWET +725% YTD to $173.78 (5/22) is now DEFLATING on US-Iran ceasefire optimism — oil -20% off peak, fund back to ~$165. SATURATED blow-off (mainstream "1,406%" coverage, lower high vs March…

Not a momentum trade — CCRN is a pinned cash-merger-arb. Aya's $18.61 deal died on FTC antitrust Dec-2025; Knox Lane (PE, no overlap) now buying at $13.25 cash, Q3-2026 close. Stock $13.12 = ~1% gross spread. No narrative leg, capped…

Cannabis-reclassification is ACCELERATING at the policy layer (April Schedule III partial reschedule; DEA broader hearing 2026-06-29), but CGC is a broken-structure value-trap proxy ($1.05, near 52-wk low) carrying a 2026-06-15 earnings…

Post-fraud holding co (Lugano Diamonds accounting scandal, dividend suspended). Narrative is DEAD, not accelerating. B. Riley Neutral / $10.50 PT on 2026-04-07 caps upside. No momentum setup — SKIP for narrative-momentum book until a clean…

Micro-cap pharma mid-transformation: a $100M Apotex asset-sale (vs $84M cap) re-rated it 3x off $1.85 lows; ifetroban pipeline (Feb-4 DMD Fast Track, Jun-2 metastasis data 0 vs 3 deaths, p=0.037) is the optionality. But the deal is priced,…

Single-asset biotech binary riding a 5-day-old Goldman initiation (Buy, $40 PT, 2026-04-17). Soquelitinib Phase 1 oral-AD readout ~2026-05-12 is the whole trade. No confirming sell-side yet, no pullback. Watch, don't buy — chase risk is…

Single-asset pediatric-oncology binary: Ojemda (tovorafenib) ramp + FIREFLY-2 front-line pLGG P3 is the whole story. DORMANT tape, no fresh catalyst inside 30d other than ~2026-05-07/14 Q1 print and ASCO 2026 abstract drop — not a…

Binary readout ALREADY FIRED: RESTORE-FA topline (2026-05-18) for DT-216P2 gapped +14% then closed -28.88% at $10.22 as open-label n=16 mFARS/biomarker data underwhelmed the run-up toward $17. Narrative leg is SPENT — no hard catalyst for…

RAS-pipeline binary catalyst. ERAS-0015 Ph1 readout narrowed to mid-May 2026 (PR 2026-04-21) stacks with AACR posters 2026-04-25 to 04-30, but the 2026-04-13 -11.52% circuit-breaker halt remains unexplained 9 sessions later. No edge to…

[Stage 1 DEFER] Q1 binary (~5/11) already cleared, dossier doesn''t show fresh ignition, CFO transition 6/1 caps conviction — sub-$1B mcap with ADV-driven slippage budget eats edge

Busted-merger special-sits: Omni deal over-levered FWRD, activists (Ancora, Irenic) forced strategic review, but 18 months on no deal has closed and Stifel just *cut* PT to $30 on 2026-04-16. Narrative velocity is negative, not…

Announced all-cash take-private: Long Lake buys Amex GBT at $9.50/share (~$6.3B), closing 2H 2026, with 69% of holders locked via voting agreements. Stock pinned at ~$9.34 — pure merger-arb, ~1.7% capped upside vs ~36% deal-break tail. No…

Small-cap specialty footwear (Journeys/J&M/Schuh) with a stale reopening tag and no accelerating narrative. Only reason to engage is a binary Q1 FY27 print (~late May 2026) with Journeys comp as the swing variable — otherwise dead tape.

M&A special-sit just broke: SiriusXM merger talks iced 2026-05-29 over a station-divestiture/antitrust impasse; the $6.56 deal-spec spike has fully round-tripped to ~$4.30. No accelerating narrative left — 5.5x-levered radio name with Adj…

Satellite-comms regulatory tailwind (FCC spectrum-sharing 7x capacity) + bullish $40 call sweep into Q1 earnings 2026-04-23 BMO. Binary print in 3 trading days = DEFER; fresh entry only on post-earnings reaction, not pre-print.

Broken-chart specialty GI biotech — Linzess royalty bleeding from Part D redesign, apraglutide SBS-IF PDUFA is the only narrative leg. Binary catalyst, not momentum. SKIP until fresh price structure or positive FDA signal re-fires the tape.

Distressed legacy carrier: CEO forced to publicly deny bankruptcy (2026-04-20 Bloomberg) while Spirit teeters and Duffy teases airline M&A. Binary Q1 print in ~1-2 weeks decides whether this becomes a Spirit-exit + takeout squeeze or a…

KALV is in a $27.00/share all-cash takeout by Chiesi (announced 2026-04-29); tender expires 2026-06-10, close expected Q3 2026. Stock pinned at $26.95 — ~0.2% spread up vs ~40% deal-break downside. Narrative fully monetized into the deal;…

Post-2026-04-08 ceasefire energy gap likely broke structure; ~2026-05-05 Q1 2026 print is the binary — need GTA cargo count ≥2 and net debt down >$150M QoQ before any long. No pre-earnings edge on a 2.5–3x levered E&P.

Post-earnings (2026-04-14) digestion still unresolved without price refresh. LOVE only matters as an a6 squeeze on a beat+raise tape against a graveyard furniture sub-sector, or as a deferred a5 pullback retest. Binary catalyst window…

⚠️ MNMD no longer trades — rebranded to Definium (DFTX) on 2026-01-15; MM120→DT120. Pure binary-catalyst psychedelic name: EMERGE (LSD in MDD) Phase 3 topline lands ~late Q2 2026, ~3 weeks out. Stock +20% into the print at ~$25 — a…

Second-derivative recovery: broadband CPE trough + AsterionX 800G optical DSP optionality into AI backplanes. Binary on Q1 FY26 print (~2026-04-28). Pre-earnings, within 3-day blackout window — no fresh entry.

Rare limit-up halt +9.30% on 2026-04-15 after Citi PT raise to $12.50 (2026-04-14) flipped NEXA from high-cost zinc laggard to Aripuanã-ramp + copper-optionality play. Binary Q1 production report due ~2026-04-28 to 2026-05-02 is the only…

Beaten-down TTFields oncology-device name (~$12, just above 52-wk low $9.82) that round-tripped its Feb Optune Pax approval; the ONLY near-term re-rate is the binary Phase 3 TRIDENT GBM overall-survival readout due by end of Q2 2026.…

Both binary catalysts already fired: Novo Nordisk $2.1B zaltenibart deal (closed 2025-12-01, $240M cash) and FDA approval of YARTEMLEA for TA-TMA (2025-12-23). Now a launch-ramp story one quarter in (Q1 net sales $9.9M). Stock $10.74, -39%…

Pre-revenue long-acting psoriasis biologic story with 6 sell-side upgrades in 9 days (Apr 6–15 2026) and zero corroborating filings — textbook pre-offering setup, not a clean narrative leg. Wait for either an S-3 print (thesis kill) or a…

Eligible on paper (rank 6/3824, +61pp vs SPX 20d, RSI 62, WSB velocity +250%, short interest 32.8%) but the dossier is unambiguous: this is a micro-cap binary ~15 calendar days from the 2026-05-07 Q1 print that must quantify the Medicare…

[Stage 1 WATCH] small-cap-ai tag but special-sit M&A thesis 18mo stale (SKT convertible), Barclays cut to Equal-Weight; RSI 83 parabolic — momentum without a fresh narrative driver.

MRD/liquid-biopsy narrative accelerating: 4 Medicare wins (May 13/19) + best-in-class ASCO data (May 29-Jun 2) drove a +70% 2-week vertical. But those catalysts already fired — a fresh entry at ~[entry redacted] just under the $11.85…

FDA-regime-change relief rally: Makary''s 2026-05-12 ouster revived hope the FDA reverses its March rejection of AMT-130''s accelerated path; +47% in 30d (to ~$30) into the 2026-06-18 AMT-260 epilepsy readout. Speculative recovery into…

RAMP signed an all-cash takeout by Publicis at $38.50/share (announced 2026-05-17, 29.8% premium). Stock gapped to the cap and now trades as a merger-arb stub — no narrative leg, upside hard-capped, closes by end-2026. The "momentum score…

RAP-219 Phase 2a FOS data (77.8% median seizure reduction, Dec 2025) pulled Phase 3 forward to Q2 2026 and drove a 5× rally to $39.71; AAN 8-wk follow-up podium on 2026-04-21 is a binary inside 24h, and current price is 6% below 52-wk high…

Binary-catalyst precision oncology setup into ASCO 2026 abstract titles (2026-05-23) and Q1 print (~2026-05-07). Split sell-side ($18 Jones Hold vs. $21 Barclays OW) = undecided market; RLY-2608 PI3Kα breast cancer data is the only thing…

Post-blowup CNS microcap in dead zone — no dated Phase 2b Sepranolone or RELIGHT readout inside 30 days. Only near-term event is the ~2026-05-15 Q1 10-Q, which is an ATM/runway reveal, not a thesis-igniter. DORMANT: watchlist only, no…

Reverse-merger special situation, NOT a momentum trade. RLYB shell popped +19% to $17.25 on 2026-06-01 Avenzo oncology merger + $215M PIPE (combined co. = AVZO, closes Q4 2026). Legacy holders get cash distribution + CVR + thin 2.8% stub;…

M&A pop is over. Real Brokerage's all-but-stock takeover (announced 4/27, $13.80 headline) is now worth only ~$9.3 blended because acquirer REAX fell to $1.66. RMAX trades at parity ($9.08) with ~34% downside on a break — a thin arb on a…

Two-activist special sit: Forager $4.80 non-binding cash bid (2026-04-17) + Veradace open letter (2026-04-09) pressing RPAY to abandon KUBRA deal and sell. Poison pill adopted 2026-04-14. Binary arb setup — topped bid to $5.25+ vs…

Asset-light freight broker sitting at the intersection of (a) late-stage freight recession inflection and (b) consolidation/activist chatter post-Coyote integration; Q1 print (~2026-05-06) is the binary — either gross margin expansion…

Pure merger-arb, narrative-dead. NBIX $53.00 cash deal announced 2026-04-06; 5 sell-side desks collapsed PTs to exactly $53 within 8 trading days. Sub-1% spread vs -35% break tail — wrong archetype for narrative-momentum book. Skip unless…

New position, not held. Rules 1/2/4/5/6 fire on momentum (rank 35/3824, +45pp vs SPX 20d, 1.76x vol, RSI 70.8, StockTwits +193% 3d/14d) and theme is ACCELERATING, but dossier discipline is explicit: archetype-5 single-asset binary on…

Post-Alcon-break special situation: shareholders killed the $30.75 takeout (Jan 6 2026); Broadwood (31%) now on the board pushing a standalone ~$50 path. China ICL recovery is real (Q1 rev +120%, EPS $0.29 vs $0.08e) but the tape already…

Cyclical semi laggard 4 trading days from Q1 2026 binary (2026-04-24). Mizuho Outperform/PT $48 upgrade 2026-04-17 marks sell-side capitulation end, but entering pre-print is gambling, not edge. DEFER until post-earnings tape confirms auto…

Closed all-cash merger, not a momentum trade: IKS Health buying TBRG at $26.25 cash (signed 2026-04-23), stock pinned ~$25.85 = ~1.5% gross spread to an expected Q3 2026 close, ~27% of shares locked to vote yes. Narrative leg already…

Small-cap workforce-housing re-rate setup: two Street PT hikes in 72h (Stifel $15 2026-04-06, Oppenheimer $18 2026-04-09) front-running a contract-award or Q1 beat. Binary catalyst — ~2026-05-07 Q1 print + any 8-K contract headline is the…

Cannabis Schedule-III reform trade back on into the 2026-06-29 DEA adult-use rescheduling hearing; sector re-accelerating but TLRY chart is busted — ~$5.12, below 200d, near 52-wk low after round-tripping $23→[entry redacted]…

Binary PRMT5i catalyst: TNG462 AACR 2026 poster drops between Apr 25–30 (abstracts Apr 21–23), repricing the stock ±30–60% in one session. No tape confirmation, no pre-data accumulation signal validated — stays DORMANT/LOW until structure…

Post-offering digestion at $13.00 anchor ahead of mid-2026 Phase 2b RIVER topline (chronic cough in IPF). Dilution overhang priced in but no clean base yet — DORMANT pending 3 closes above $13.50 on fading volume. Archetype-5 binary,…

FILSPARI FSGS approval fired 2026-04-14 with 6 same-day PT hikes ($44–$56); T+8 sessions into post-binary drift window. DORMANT until either a weekly close above 2026-04-14 gap-high on >1.5x volume (breakout entry) OR Q1 print…

Post-Windstream merger fiber REIT with 47% analyst PT spread (RBC $7.50 vs Barclays $11, both mid-April 2026). Archetype-5 binary: Q1 2026 print ~May 6–9 is the only thing that matters. DORMANT until that tape resolves deleveraging pace…

Long-oil geopolitical premium (USO) is SATURATED at a binary inflection: Iran exports at a 6-yr low + summer-squeeze warnings keep it bid, but the pending US–Iran 4-stage deal explicitly lifts oil restrictions — the most likely near-term…

Post-COVID biotech pivot — VIR-5500 Phase 1 (PSMA dual-masked TCE) first patient dosed 2026-04-13; AACR 2026-04-25→30 posters and Q1 2026 earnings (~early May) are the next binary inflections. DORMANT until first-cohort safety disclosure…

[Stage 1 WATCH] Mis-tagged: dossier explicitly says zero AI/HBM exposure, analog auto-cycle name, archetype-5 binary cleared without conviction — not a narrative-momentum trade.

Not a momentum setup — a binary Nasdaq delisting/shell rescue. XTLB ($5.6M cap, $2.23, at 52-wk low) is a public shell on a conditional listing exception; must close the Psyga Bio reverse-merger + $1.5M raise and regain full compliance by…